The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SDGR | -1.69% | -64.78% | -18.83% | -35% |
| S&P | +13.35% | +91.49% | +13.87% | +101% |
Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.
Its groundbreaking work is winning it some powerful fans, but it's still risky.
There's more to the AI boom than Microsoft and ChatGPT.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $54.32M | 53.9% |
| Gross Profit | $28.04M | 58.2% |
| Gross Margin | 51.61% | 1.4% |
| Market Cap | $1.48B | 9.3% |
| Market Cap / Employee | $1.66M | 0.0% |
| Employees | 891 | 2.8% |
| Net Income | -$32.80M | 14.0% |
| EBITDA | -$44.48M | 33.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $181.87M | 6.9% |
| Accounts Receivable | $29.38M | 121.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $94.69M | -8.3% |
| Short Term Debt | $16.74M | -0.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -26.61% | -2.3% |
| Return On Invested Capital | -15.26% | -2.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$62.36M | -80.3% |
| Operating Free Cash Flow | -$61.87M | -86.1% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 68.99 | - | |||
| Price to Book | 3.13 | 3.41 | 3.95 | 4.31 | 43.19% |
| Price to Sales | 6.77 | 6.26 | 6.21 | 5.75 | -17.73% |
| Price to Tangible Book Value | 3.16 | 3.45 | 4.00 | 4.37 | 43.67% |
| Price to Free Cash Flow TTM | 65.08 | 60.62 | - | ||
| Enterprise Value to EBITDA | -60.60 | -21.22 | -21.98 | -26.69 | 66.40% |
| Free Cash Flow Yield | 1.5% | 1.6% | - | ||
| Return on Equity | -38.6% | -43.3% | -44.4% | -45.7% | 30.25% |
| Total Debt | $117.83M | $116.16M | $114.31M | $111.43M | -7.25% |
No podcast episodes available.
SDGR earnings call for the period ending June 30, 2022.
SDGR earnings call for the period ending March 31, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
